France is aiming to become a global AI superpower — but not without help from U.S. Big Tech
French President Emmanuel Macron speaks during a meeting with members of the AI sector at the Elysee Presidential Palace in Paris, France, on May 21, 2024.
Yoan Valat | Afp | Getty Images
PARIS — France is touting itself as the next artificial intelligence superpower.
The Viva Technology conference in Paris last week was buzzing with talk about how far France has come as a leader in AI.
A great deal of chatter surrounded the French AI firm H, previously named Holistic, which raised $220 million in a seed funding round from investors including U.S. tech giant Amazon and Google’s billionaire ex-CEO Eric Schmidt.
A common theme for French AI firms receiving large sums of money is that they’re adding U.S. tech heavyweights to their shareholder lists.
Earlier this month, France received a flood of new private investments, led by a commitment from Microsoft of 4 billion euros ($4.4 billion), its largest ever into France.
AI everywhere at Viva Tech
At Viva Tech, AI was everywhere. Past the large, bright pink “VIVA” sign toward the front, there was an entire alley called “AI Avenue,” which was surrounded by U.S. tech firms such as Salesforce and AWS.
Generative AI was on display everywhere — even from companies you wouldn’t expect.
For example, French beauty giant L’Oreal showed off an AI-powered beauty assistant called “BeautyGenius” at a large booth near the center of the Porte de Versailles conference venue.
The success of Viva Tech has become symbolically important for France as part of its bid to become a leading tech and AI hub that can rival the likes of the U.S. and China.
“France is the leader on artificial intelligence in Europe,” Bruno Le Maire, France’s finance minister, told CNBC’s Arjun Kharpal at Viva Tech last week.
He made clear that, while France has a helping hand from U.S. tech giants, “we want to have our own artificial intelligence being created and being developed in France.”
Referring to Microsoft’s investment in France, Le Maire said, “Microsoft is much welcome in our country. But the challenge for us is to have our own devices, our own scientists … and we are working very hard for that.”
France boasts a strong AI research and development ecosystem, home to key facilities like the Facebook AI Research center from Meta and Google’s AI research hub in Paris, as well as leading universities.
“France stands as one of Europe’s most vibrant innovation hubs,” Etienne Grass, the France managing director of Capgemini Invent, the digital innovation arm of Capgemini, told CNBC. “The nation nurtures a thriving startup scene, marked by significant strides in AI,” Grass added.
Imran Ghory, partner at Blossom Capital, said that while France has a great track record when it comes to research and academia, it has struggled to funnel quality talent into “great companies.”
AI labs from Meta and Google have “created a training ground for students and researchers to learn what leading tech companies look and work like from the inside,” Ghory said.
“We’re now seeing the fruits of this as many researchers and AI engineers begin spinning out their own companies.”
Vying for tech leadership
French President Emmanuel Macron told CNBC’s Andrew Ross Sorkin in an interview last week that his country is “leading the tech industry in Europe.” However, he noted Europe is “lagging behind” the U.S. and that the continent needs more “big players.”
“It’s insane to have a world where the big giants just come from China and the U.S,” Macron told said at the Elysee Palace. He praised Mistral, the French AI firm backed by U.S. tech giant Microsoft, and H.
Last week, Macron met with Eric Schmidt, former CEO of Google, Yann LeCun, chief AI scientist of Meta, and James Manyika, Google’s senior vice president of tech and society, among others, at the Elysee to discuss ways to make Paris a global AI hub.
Maurice Levy, CEO of advertising and public relations giant Publicis Groupe, told CNBC’s Karen Tso he thinks France has the potential to become a top five country for AI development. Levy said France is “determined” to narrow the gap between the U.S. and China and Europe when it comes to AI.
France “can be part of the five biggest countries on AI in the world,” after the U.S., China, Israel, and the U.K., Levy said in a TV interview last week. He referred to H’s mammoth funding round as an example of the momentum surrounding French AI right now.
Levy said roughly 40% of the tech demos at Viva Tech were AI. AI is “something which is … not only taking off, but has already taken off quite massively,” he said.
In a fireside discussion last week, Google’s Manyika said a lot of the innovation the firm has been bringing to the table is sourced from engineers in France.
He said that Google’s recently introduced Gemma AI, a lightweight, open-source model, was developed heavily at the U.S. internet giant’s Paris AI hub.
According to data from Dealroom, France claimed a roughly 20% share of overall European AI startup funding in 2023, higher than the 15% average of European funding that goes into AI startups across the bloc.
France isn’t the European AI leader, though, according to Dealroom, with U.K. firms raising more than double the amount of both AI and GenAI investment than France.
Innovation versus regulation
France’s Macron said the challenge for Europe is accelerating AI research and development while also regulating at “appropriate scale.”
Last week, the EU approved the AI Act, a landmark law regulating artificial intelligence.
Some tech executives warned Europe could hamper its AI ambitions with regulation that is too restrictive. France has been among the countries to have criticized the EU AI Act for being too restrictive when it comes to innovation.
Pascal Brier, Capgemini’s chief innovation officer, said while regulation is needed to ensure AI isn’t left to become too powerful, it’s important to ensure new laws like the AI Act don’t accidentally “kill” innovation.
He said regulators should avoid implementing the “principle of precaution” — the idea that AI makers should avoid doing things that can do harm, as a rule.
“There’s no way you can stop AI — it’s only the end of the beginning,” Brier told CNBC. “It’s not going to stop there.”
Go back a decade and most Americans had never heard of Huawei. Today, the Chinese telecom giant is a symbol of how quickly China can dominate a strategic technology sector and in the process create new national security and market threats for U.S. government and industry.
Democratic Senator Mark Warner of Virginia, the top Democrat on the Senate Select Committee on Intelligence, is now worried about another Chinese company that he predicts will eclipse Huawei in both scale and consequence: BGI. It is not building cell towers or smartphones for the 5G era. It is collecting DNA.
“If Huawei was big, BGI will be even bigger,” Warner said at the CNBC CFO Council Summit in Washington, D.C. on Wednesday.
BGI is one of the largest genomics companies in the world. It operates DNA sequencing laboratories in China and abroad. It processes genetic data for hospitals, pharmaceutical firms and researchers across dozens of countries, according to a recent report by the National Security Commission on Emerging Biotechnology.
The company began as a Beijing-based research entity, the Beijing Genomics Institute, tied closely to China’s national genome projects. It later expanded into a global commercial powerhouse, selling DNA sequencing, prenatal testing, cancer screening, and large-scale population genetic analysis, according to an NBC News report.
Through subsidiaries, BGI says it operates in the U.S. Europe, and Japan. In several countries, it helped built national genetic databases and pandemic testing systems.
A man visits the booth of BGI at the Healthy Life Chain area of the third China International Supply Chain Expo CISCE in Beijing, capital of China, July 16, 2025.
Xinhua News Agency | Xinhua News Agency | Getty Images
U.S. intelligence officials believe that global footprint gives BGI access to one the largest collections of genetic data on Earth. Lawmakers have warned that genetic data is not just medical information. At scale, it becomes a strategic asset spurring a “DNA arms race,” according to a Washington Post report. DNA profiles can reveal ancestry, physical traits, disease risk, and family relationships, and when linked with artificial intelligence, the data can also be used for surveillance, tracking and long-term biological research tied to national security, according to the Washington Post’s reporting.
At the CNBC event this week, Warner continued to press for more focus on BGI. “They are hoovering up DNA data,” Warner said. “This level of experimentation on humans and intellectual property theft, we all should be concerned about it.”
Congressional investigators have previously warned that BGI maintains close ties to the Chinese Communist Party and Chinese military, according to a report from the House Select Committee on the CCP. They argue that China makes little distinction between commercial data and state security needs.
The ‘super soldier’ fear
One of the biggest fears tied to BGI and China’s broader biotech push is the possibility of a genetically enhanced soldier. U.S. officials have publicly claimed that China has explored human performance enhancement and military biotechnology. U.S. defense analysts say China’s research spans population DNA collection, military databases, and AI-driven human performance modeling, according to a Wall Street Journal op-ed written by U.S. Director of the Central Intelligence Agency John Ratcliffe in 2020, when he was Director of National Intelligence during President Trump’s first term.
Warner directly referenced those concerns this week.
“It’s terrifying,” Warner said.
Troops make preparations before a military parade in Beijing, capital of China, Sept. 3, 2025.
Xinhua News Agency | Xinhua News Agency | Getty Images
Warner described China as a great nation and great competitor, and as a former telecom executive (he was among the founders of Nextel), he said what Huawei was able to execute on — producing good products at inexpensive prices before the U.S. and Western competitors were prepared — is a cautionary tale.
The BGI story looks uncomfortably familiar to Warner.
“Go back in time eight or nine years, and most people had never heard of Huawei,” he said.
Huawei rose by combining massive state support, global market access and aggressive pricing, not only outcompeting Western firms on scale and cost, but positioning itself inside the world’s telecom infrastructure before governments understood the security implications. Huawei was first placed on a U.S. trade blacklist in 2019, which banned U.S. firms from selling some technology to the Chinese tech giant over national security concerns. Chip restrictions on Huawei have since become even stricter.
But Warner said by the time the U.S. moved to restrict Huawei, “[we started to] lose a little.”
Much of the 5G backbone had already been shaped by Chinese technology.
During a separate interview with Javers at the CNBC CFO Council Summit, the Republican Chairman of the House committee on the Chinese Communist Party, Michigan congressman John Moolenaar, said “We’ve seen how they run the play of excess capacity, price manipulation, driving people out of business in different areas; they’re going to continue to run that play,” he said. “We want to be friendly with China, but China is not our friend. They are our foremost adversary,” he added.
The Soviet Union was a military and ideological competitor, but China, in tech domain after domain, Warner says — from telecom and 5G to AI, quantum computing and biotech — is a different kind of competitor.
Warner now sees BGI following a similar model in biotechnology. Like Huawei, BGI scaled rapidly with state support. The Washington, D.C.-based think tank Foundation of Defense of Democracies called upon lawmakers of both parties earlier this year to restrict BGI’s access to U.S. institutions.
Congress has been trying to pass various versions of the BIOSECURE Act, which would limit the ability of Chinese biotechs to operate in the U.S. Some U.S. hospitals and research institutions with ties to Chinese genomics firms are under federal pressure, according to the Associated Press, though some medical professionals within the U.S. say they risk losing key research support for core medical goals. BGI told the AP that the bill is “a false flag targeting companies under the premise of national security. We strictly follow rules and laws, and we have no access to Americans’ personal data in any of our work,” it said.
U.S. intel has moved too slowly, and disrupted key spying alliances
Warner said the U.S. intelligence apparatus has moved too slowly to recognize the biotech threat. He says that intelligence agencies focus too much on foreign governments and militaries, with less attention placed on commercial technology sectors. But in a world where technology supremacy is national security, Warner says more of our intelligence efforts need to reflect this shift.
Only in the past two to three years, he says, has the U.S. seriously expanded spying into AI, semiconductors, and biotechnology. Warner says we need a more “advanced approach” in this area, and he gave as one recent example when China’s largest chipmaker SMIC stunned U.S. officials by producing a six-nanometer chip despite sweeping U.S. export controls. The breakthrough showed that Washington had underestimated both China’s technical qualities and ability to work around restrictions. “We got caught off guard with the SMIC six-nanometer chip,” Warner said.
Warner is also worried that tracking China’s tech rise requires a type of deep cooperation with U.S. allies that the Trump administration has squandered, such as the global intelligence-sharing network called the “Five Eyes” alliance.
Those relationships are now under strain, he said, and key partners including the United Kingdom, the Netherlands, and France have gone public in saying they are reluctant to share intel with the U.S. “They feel like we may be politicizing the intel product and that is not good news for America,” Warner said.
Underlying his concerns about the technology competition with China in areas including AI and biotech is the U.S. ceding the global lead in standards setting. For decades, the U.S. shaped the rules for wireless networks, satellites, and internet infrastructure. That dominance help Americans lead global markets, Warner said, but now China is aggressively positioning itself as the international standards setter.
Warner described the U.S. role in international bodies as one of the “secret sauces” in the era of America’s dominance of the global economy and technology, allowing the U.S. to leverage innovations occurring around the globe, “even if it didn’t arise in America.”
Across technology domains, influencing standards and protocols is critical to not only maintaining a competitive edge but also establishing ethical boundaries. “Will it be us or the Chinese?” Warner said. “The Chinese come in with clearly a less humanist approach. It’s been effective in lots of domains. We see it on standards-setting bodies. China floods the zone with lots of engineers, almost buying off the votes. We’ve got to reengage for American business and government,” he said.
-
Sports2 years agoStory injured on diving stop, exits Red Sox game
-
Sports3 years ago‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports2 years agoGame 1 of WS least-watched in recorded history
-
Sports3 years agoButton battles heat exhaustion in NASCAR debut
-
Sports3 years agoMLB Rank 2023: Ranking baseball’s top 100 players
-
Sports4 years ago
Team Europe easily wins 4th straight Laver Cup
-
Environment3 years agoJapan and South Korea have a lot at stake in a free and open South China Sea
-
Environment1 year agoHere are the best electric bikes you can buy at every price level in October 2024